NON SMALL CELL LUNG CANCER METASTATIC
Clinical trials for NON SMALL CELL LUNG CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CANCER METASTATIC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 17, 2026 03:40 UTC
-
Hope for elderly lung cancer patients: immunotherapy combo under study
Disease control OngoingThis study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemotherapy alone or chemotherapy plus atezolizumab. The …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Triple threat: new combo aims to extend lung cancer survival
Disease control OngoingThis study tests whether adding radiation to a standard treatment of immunotherapy (pembrolizumab) plus chemotherapy can help people with advanced non-small cell lung cancer live longer. About 327 participants with stage IIIB or IV disease will receive the combination therapy. Th…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New hope for Hard-to-Treat lung cancer: which combo works best?
Disease control OngoingThis study tests two different chemotherapy plus immunotherapy combinations in people with advanced lung cancer that has a specific marker (TTF-1 negative). About 136 participants will be randomly assigned to one of two treatment groups. The goal is to see which combination helps…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE4 • Sponsor: Nikolaj Frost MD • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New timing for lung cancer combo shows promise in early trial
Disease control OngoingThis study tests two different timing schedules of a drug combination (durvalumab, pemetrexed, and carboplatin) in adults with advanced non-squamous non-small cell lung cancer. The goal is to see if staggering the doses improves how long the cancer is controlled. 43 participants …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Zapping spreading tumors early may buy time for cancer patients
Disease control OngoingThis study tests whether giving precise radiation to tumors that have just started to grow can delay the cancer from getting worse. It involves 107 adults with metastatic triple-negative breast cancer or non-small cell lung cancer. Participants are randomly assigned to receive ei…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for rare lung cancer mutations: targeted pill shows promise
Disease control OngoingThis study tests a daily pill called dacomitinib in 30 people with advanced lung cancer that has uncommon EGFR gene mutations. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug until their cancer worsens or they no longer benefit, an…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug combo targets Hard-to-Treat liver and lung cancers
Disease control OngoingThis study tests the drugs atezolizumab and bevacizumab in people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. Researchers want to see how long the cancer stays under control and how the tumors change during treatment. About 36 adults w…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for rare lung cancer: lorlatinib targets resistant tumors
Disease control OngoingThis study tests a drug called lorlatinib in people with a rare, advanced lung cancer that has a specific genetic change (ROS1-positive). Participants have already tried a first-line treatment that stopped working. The goal is to see if lorlatinib can shrink tumors and keep the c…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for tough lung cancers: drug combo trial launches
Disease control OngoingThis trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, in people with advanced non-small cell lung cancer that has come back or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously e…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Experimental cocktail targets tough lung cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain genetic markers (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Triple-Drug attack shows promise against tough lung cancer
Disease control OngoingThis study tests whether combining three drugs—nivolumab, ipilimumab, and nintedanib—can shrink tumors in people with advanced non-small cell lung cancer that cannot be cured. About 66 adults with no other treatment options will take part. The goal is to find the safest dose and …
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New hope for lung cancer patients after immunotherapy stops working
Disease control OngoingThis study tests a combination of three drugs (bevacizumab, nab-paclitaxel, and platinum) as a second treatment for people with advanced non-squamous non-small cell lung cancer that does not have certain gene mutations. The participants' cancer had already gotten worse after firs…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Computer nudge could Fast-Track lung cancer treatment decisions
Knowledge-focused OngoingThis study looks at whether an electronic reminder in the health record system can help doctors order genetic tests earlier for people newly diagnosed with advanced non-small cell lung cancer. The goal is to have test results ready before starting treatment, so doctors can choose…
Matched conditions: NON SMALL CELL LUNG CANCER METASTATIC
Phase: NA • Sponsor: Charu Aggarwal • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:06 UTC